Mode
Text Size
Log in / Sign up
N/A N=40 Other

Effect of Waterpipe Size on Smoking Behavior and Exposures

Waterpipe Size

Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Nov 2025
Primary outcome: Primary: Waterpipe Evaluation Scale — 4.2; 4.4; 4.7 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Waterpipe size (Other)
Age
Adult · 21+ yrs
Sex
All
Sponsor
The University of Texas at Arlington
Primary completion
Feb 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Waterpipe Evaluation Scale
4.2; 4.4; 4.7
PRIMARY
Duke Sensory Questionnaire
4.4; 4.0; 3.8
PRIMARY
Harm Perception Questionnaire
3.5; 3.7; 3.8
PRIMARY
Saliva Nicotine
1065.5; 620.2; 701.4
PRIMARY
Puff Topography: Smoking Time
38.05; 35.5; 36.27
PRIMARY
Puff Topography: Cumulative Puff Time
5.10; 5.10; 6.67
PRIMARY
Puff Topography: Puff Duration
2.15; 2.20; 2.45
PRIMARY
Puff Topography: Average Flow Rate
15.14; 16.65; 18.92
PRIMARY
Puff Topography: Number of Puffs
161.05; 162.31; 182.90
PRIMARY
Puff Topography: Total Smoke Volume Inhaled
76.82; 79.85; 116.19
PRIMARY
Puff Topography: Puff Volume Average
0.57; 0.64; 0.78
PRIMARY
Puff Topography: Maximum Puff Volume
1.21; 1.34; 1.62

Summary

The goal of this clinical trial is to learn how waterpipe (WP) size affects smoking behavior, toxicant exposure, and subjective experiences in young adult WP smokers (ages 21-39). The main questions it aims to answer are: * Does WP size change puffing behavior? * Does WP size change exposure to nicotine and carbon monoxide? * Does WP size change perceptions of harm, satisfaction, craving, or withdrawal? Participants will smoke small, medium, and large WPs in separate sessions. Researchers will measure puffing behavior, saliva nicotine, exhaled carbon monoxide, and survey responses before and after each session.

Eligibility Criteria

Inclusion Criteria

  • regular waterpipe smokers (smoking at least once a week for the past 6 months)
  • generally healthy and
  • able to provide written informed consent; and willing to attend the 3 lab sessions

Exclusion Criteria

  • history of chronic diseases such as diabetes, high blood cholesterol, hepatic disease
  • respiratory chronic diseases
  • cardiovascular diseases including low or high blood pressure (BP)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05705375). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search